Top

Cancer Causes & Control

Published in:

01-05-2018 | Original paper

Trends of two HPV-associated cancers in Massachusetts: cervical and oropharyngeal cancer

Authors: Erin E. Cook, Susan T. Gershman, Jane J. Kim, Rulla M. Tamimi, R. Monina Klevens, Michelle D. Holmes

Published in: Cancer Causes & Control | Issue 4-5/2018

Abstract

Purpose

To understand trends in the incidence and mortality of two human papillomavirus (HPV)-associated cancers, cervical and oropharyngeal cancer, in Massachusetts.

Methods

From 2004 to 2014, the Massachusetts Cancer Registry recorded 3,996 incident cases of oropharyngeal cancer and 2,193 incident cases of cervical cancer. Mortality data were obtained from the Massachusetts Registry of Vital Records and Statistics from 2008 to 2014. Rates were age-standardized to the 2000 U.S. population and trends were assessed using joinpoint regression.

Results

While the incidence rate of cervical cancer (5.46 per 100,000) decreased by 2.41% annually (p = 0.004), the incidence rate of oropharyngeal cancer among males (7.85 per 100,000) increased by 2.82% annually (p = 0.0002). Mortality rates for both cancers decreased from 2008 to 2014 but were not statistically significant (cervical − 3.73% annually, p = 0.29; oropharyngeal − 1.94% annually, p = 0.44).

Conclusion

The rising incidence rate of oropharyngeal cancer in men and the decreasing, but relatively high, incidence rate of cervical cancer in women highlight the need for further screening and prevention by HPV vaccination in Massachusetts.

Available only for authorised users

Saraiya M, Unger ER, Thompson TD et al (2015) US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. JNCI J Natl Cancer Inst 107(6):djv086. https://doi.org/10.1093/jnci/djv086 CrossRefPubMed

Viens LJ, Henley SJ, Watson M et al (2016) Human papillomavirus–associated cancers—United States, 2008–2012. MMWR Morb Mortal Wkly Rep 65:661–666. https://doi.org/10.15585/mmwr.mm6526a1 CrossRefPubMed

Centers for Disease Control and Prevention HPV Cancer [online] (2016) https://www.cdc.gov/cancer/hpv/statistics/cases.htm. Accessed 22 Mar 2017

U.S. Department of Health and Human Services (DHHS) (2017) National Center for Health Statistics. The 2016 National Immunization Survey—Teen, Hyattsville: Centers for Disease Control and Prevention

United States Census Bureau. QuickFacts Massachusetts [online] (2016) https://www.census.gov/quickfacts/table/PST045216/25. Accessed 29 Mar 2017

North American Association of Central Cancer Registries (NAACCR). Certified Registries [online] (2016) https://www.naaccr.org/certified-registries/. Accessed 7 June 2017

Joinpoint Regression, Program, Version 4.4.0.0 - January 2017; Statistical Methodology and Applications Branch, Surveillance Research Program, National Cancer Institute

SAS 9.3. Cary, NC, USA: SAS Institute Inc

Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Population Health. BRFSS Prevalence & Trends Data [online] (2015) https://www.cdc.gov/brfss/brfssprevalence/. Accessed 10 May 2017

10.

National Institute on Alcohol Abuse and Alcoholism. Surveillance Report #102 Apparent Per Capita Alcohol Consumption: National, State, and Regional Trends, 1977–2013. https://pubs.niaaa.nih.gov/publications/surveillance102/tab4-3_13.htm. Accessed 17 May 2017

11.

Dunne EF, Unger ER, Sternberg M et al (2007) Prevalence of HPV infection among females in the United States. JAMA 297(8):813–819. https://doi.org/10.1001/jama.297.8.813 CrossRefPubMed

12.

Centers for Disease Control and Prevention (1993–2015) Youth Risk Behavior Survey Questionnaire. http://www.cdc.gov/yrbs. Accessed 17 May 2017

13.

Chaturvedi AK, Engels EA, Pfeiffer RM et al (2011) Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 29(32):4294–4301. https://doi.org/10.1200/JCO.2011.36.4596 CrossRefPubMedPubMedCentral

14.

SEER Cancer Stat Facts: Cervix Uteri Cancer. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/statfacts/html/cervix.html

15.

Howlander N, Noone AM, Krapcho M et al (2016) SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. Bethesda, MD. https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site April 2017

16.

Centers for Disease Control and Prevention. Gynecologic Cancers: Cervical Cancer Rates by Race Ethnicity [online] (2017) https://www.cdc.gov/cancer/cervical/statistics/race.htm. Accessed 15 Jan 2018

17.

Pytynia KB, Dahlstrom KR, Sturgis EM (2014) Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncol 50(5):380–386. https://doi.org/10.1016/j.oraloncology.2013.12.019 CrossRefPubMedPubMedCentral

18.

Herbenick D, Reece M, Schick V et al (2010) Sexual behavior in the United States: results from a national probability sample of men and women ages 14–94. J Sex Med 7(Suppl 5):255–265CrossRefPubMed

19.

Meites E, Kempe A, Markowitz LE (2016) Use of a 2-dose schedule for human papillomavirus vaccination—updated recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mort Wkly Rep 65:1405–1408. https://doi.org/10.15585/mmwr.mm6549a5 CrossRef

20.

Massachusetts Department of Public Health, Health Survey Program. Data Brief: Massachusetts Adolescent Health: Sexual Health, Experiences, and Behaviors (Spring 2016) http://www.mass.gov/eohhs/docs/dph/behavioral-risk/mass-adole-health-sexual-health.pdf. Accessed 17 May 2017

21.

Addison D, Seidelmann SB, Jangua SA et al (2017) Human papillomavirus status and the risk of cerebrovascular events following radiation therapy for head and neck cancer. J Am Heart Assoc 6(9):e006453CrossRefPubMedPubMedCentral

22.

Lorch JH, Hanna GJ, Posner MR et al (2015) Human papillomavirus and induction chemotherapy versus concurrent chemoradiotherapy in locally advanced oropharyngeal cancer: the Dana Farber experience. Head Neck 38(S1):E1618–E1624

23.

Nelson HH, Pawlita M, Michaud DS et al (2017) Immune response to HPV16 E6 and E7 proteins and patient outcomes in head and neck cancer. JAMA Oncol 3(2):178–185CrossRef

24.

Nichols AC, Finkelstein DM, Faquin WC et al (2010) Bcl2 and human papilloma virus 16 as predictors of outcome following concurrent chemoradiation for advanced oropharyngeal cancer. Clin Can Res 16(7):2138–2146CrossRef

25.

Ringstrom E, Peters E, Hasegawa M et al (2002) Human papillomavirus type 16 and squamous cell carcinoma of the head and neck. Clin Cancer Res 8(10):3187–3192PubMed

26.

Stang A, Hawk H, Knowlton RK et al (2014) Hysterectomy-corrected incidence rates of cervical and uterine cancers in Massachusetts, 1995 to 2010. Ann Epidemiol 24(11):849–854CrossRefPubMed

27.

Massachusetts Department of Public Health. Massachusetts Comprehensive Cancer Prevention and Control Network (2017) http://www.mass.gov/eohhs/gov/departments/dph/programs/community-health/cancer-prev-and-control/program-structure.html. Accessed 19 July 2017

28.

Wagner R, Villa A (2107) Oral human papillomavirus infections and the role of the dental professional. J Massachusetts Dent Soc 65(4):12–15

29.

Massachusetts Cancer Registry, Massachusetts Department of Public Health (2018) http://www.mass.gov/dph/mcr. Accessed 12 Jan 2018

Title: Trends of two HPV-associated cancers in Massachusetts: cervical and oropharyngeal cancer
Authors: Erin E. Cook
Susan T. Gershman
Jane J. Kim
Rulla M. Tamimi
R. Monina Klevens
Michelle D. Holmes
Publication date: 01-05-2018
Publisher: Springer International Publishing
Published in: Cancer Causes & Control / Issue 4-5/2018
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-018-1016-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 4-5/2018

Prospective evaluation of serum IL-16 and risk of prostate cancer in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Muscle-strengthening and aerobic activities and mortality among 3+ year cancer survivors in the U.S.

Pre-diagnostic aspirin use and mortality after breast cancer

An update in international trends in incidence rates of thyroid cancer, 1973–2007

Residential traffic noise and mammographic breast density in the Diet, Cancer, and Health cohort

A spatiotemporal analysis of invasive cervical cancer incidence in the state of Maryland between 2003 and 2012

Keynote webinar | Spotlight on antibody–drug conjugates in cancer